A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective , open, multicenter, randomized phase III study. The investigators
planed to include 380 untreated high risk T cell lymphoma adults,to random to CHOP and c-ATT
regimen groups after signature the informed consents. The patients will receive safety
assessment every cycles, and efficacy evaluation every 3 cycles. Every-two-months follow up
will be received after finishing the treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Chinese Academy of Medical Sciences Fudan University Tianjin Medical University Cancer Institute and Hospital